Method for discriminating between prostate cancer and a benign prostate disease

Abstract

A method of analyzing diagnostic information for estimating which of a benign prostate disease and prostate cancer is affecting a subject to be diagnosed combines two methods of analyzing diagnostic information. The first method includes measuring a concentration of a mucin-1 (Tn-MUC1), reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine->serine(threonine) residue, in a subject blood sample, comparing the measured value with a threshold value, and estimating that a disease affecting the subject is benign prostate disease when the measured value is greater than the threshold value. The second method includes measuring a concentration of a prostate-specific antigen (LacdiNAc-PSA), reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine B1-4 N-acetylglucosamine residue in the blood sample, comparing the measured value with a threshold value, and estimating that the disease affecting the subject is prostate cancer when the measured value of LacdiNAc-PSA is greater than the threshold value.

1 . A method of analyzing diagnostic information for estimating which of a benign prostate disease and prostate cancer is affecting a subject to be diagnosed, the method using a combination of:
 a method of analyzing diagnostic information that comprises:
 measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine->serine(threonine) residue, in a blood sample from the subject to be diagnosed; 
 comparing the measured value with a threshold value; and 
 estimating that a disease affecting the subject to be diagnosed is not prostate cancer but the benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value; and 
   a method of analyzing diagnostic information that comprises:
 measuring a concentration of a prostate-specific antigen (LacdiNAc-PSA), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine B1-4 N-acetylglucosamine residue in the blood sample from the subject to be diagnosed; 
 comparing the measured value with a threshold value; and 
 estimating that the disease affecting the subject to be diagnosed is not the benign prostate disease but prostate cancer when the measured value of the concentration of LacdiNAc-PSA is greater than the threshold value.